Regulated information
Waregem (Belgium)/Rotterdam (Netherlands)[1], 31 December 2015
Further to the press release of 14 December 2015, Fagron recently had constructive talks with its financing banks and with other parties regarding a possible public or private capital increase.
Fagron is pleased to announce that it has been granted a waiver by its financiers in respect of the financial covenants on the revolving credit facility and the US private placement. This waiver is valid till the end of March 2016. This means that during this period, Fagron will not be required to fulfil the financial covenants applying to the loans. This will allow Fagron to concentrate on the possible public or private capital increase to safeguard its financial situation for the longer term as well.
In the event of any discrepancies between the English translation and the original Dutch version of this press release, the latter shall prevail.
For more information:
Constantijn van Rietschoten
Chief Marketing Officer / Investor Relations a.i.
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com
Fagron profile
Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
[1] This press release was sent out by Fagron NV and Fagron BV.
Please open the link below for the press release:
